PARIS, December 4 /PRNewswire-FirstCall/ -- ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, is pleased to announce today that it has been honoured by the INPI (National Institute of Industrial Property) during the last edition of its "Trophee de l'Innovation" (Innovation Trophy).
"Since its inception, ExonHit consistently made efforts to maintain and to protect the value of its intellectual property and in particular from its international patents. The discovery activities has allowed the Company to reach a leading intellectual property position, in the field of alternative splicing technologies as well as for drug candidates and innovative diagnostic solutions. This wide position is a true asset which results today in a portfolio of 204 international patents", declared Frederique Schlumberger, general counsel of ExonHit Therapeutics.
Loic Maurel, Chairman of the Executive Board of ExonHit Therapeutics, added : "I'm very proud to receive from the INPI this award in the name of all our teams of researchers who work for the company on a daily basis. This distinction is all the more symbolic in that it occurs at a key time of our development. Actually, in a few months, ExonHit is preparing the release of a first range of blood diagnostic tests for Alzheimer's disease in which all our collaborators have provided strong support to us. This future success would have never happened without a dedicated attention to defending our intellectual property. These patents are critical in our industry. They precede industrial successes and the creation of value of biotechnology companies like ExonHit ".
A ceremony took place this day in Paris, in the presence of Benoit Battistelli, General manager of the INPI, and Marc Antoine Jamet, President of the Union of the Manufacturers.
About ExonHit Therapeutics
|SOURCE ExonHit Therapeutics SA|
Copyright©2008 PR Newswire.
All rights reserved